ALK and non-small cell lung carcinoma: Concerning NSCLC patients, only one study has investigated the prognostic worthiness of PIV in this patient population [34], which explored the prognostic significance of PIV in 94 patients with advanced anaplastic lymphoma kinase (ALK)-positive NSCLC who had received first-line ALK inhibitors.